natgillin/translations-raw huggingface dataset:
Simparica was as effective as moxidectin and imidacloprid in eliminating live mites in skin scrapings.
Simparica je bio podjednako djelotvoran kao moksidectin i imidakloprid u eliminaciji živih uši u kožnim strugotinama.
Simparica was as effective as spinosad in reducing flea counts for up to 90 days after treatment.
Simparica je bio podjednako djelotvoran kao sponosad u smanjivanju broja buha u trajanju do 90 dana nakon terapije.
Simple partial
jednostavni parcijalni
Simponi 100 mg is not recommended for children and adolescents (younger than 18 years).
Simponi 100 mg se ne preporučuje u djece i adolescenata (mlađih od 18 godina).
Simponi 100 mg is not recommended in children aged less than 18.
Ne preporučuje se primjena lijeka Simponi 100 mg u djece mlađe od 18 godina.
Simponi 100 mg solution for injection in pre-filled pen golimumab
Simponi 100 mg otopina za injekciju u napunjenoj brizgalici golimumab
Simponi 100 mg solution for injection in pre-filled syringe golimumab
Simponi 100 mg otopina za injekciju u napunjenoj štrcaljki golimumab
Simponi 200/100 mg N = 253
Simponi 100 mg
Simponi 50 mg administered once a month, on the same date each month, for children with a body weight of at least 40 kg.
Primjenjuje se 50 mg lijeka Simponi jedanput na mjesec, istoga dana u mjesecu, u djece s tjelesnom težinom od najmanje 40 kg.
Simponi 50 mg solution for injection in pre-filled pen golimumab
Simponi 50 mg otopina za injekciju u napunjenoj brizgalici golimumab
Simponi 50 mg solution for injection in pre-filled pen golimumab
Simponi 50 mg otopina za injekciju u napunjenoj štrcaljki golimumab
Simponi 50 mg solution for injection in pre-filled syringe golimumab
Simponi 50 mg otopina za injekciju u napunjenoj štrcaljki golimumab
Simponi 50 mg treatment reduced the rate of progression of peripheral joint damage compared with placebo treatment at week 24 as measured by change from baseline in total modified vdH-S Score (mean ± SD score was 0.27 ± 1.3 in the placebo group compared with -0.16 ± 1.3 in the Simponi group; p = 0.011).
Broj bolesnika u kojih nije bilo novih erozija ili je promjena u odnosu na početno stanje ukupnog broja bodova na vdH-S ljestvici iznosila ≤ 0 bio je značajno veći u skupini liječenoj lijekom Simponi nego u kontrolnoj skupini (p = 0,003).
Simponi 50 mg treatment reduced the rate of progression of peripheral joint damage compared with placebo treatment at week 24 as measured by change from baseline in total modified vdH-S Score (mean ± SD score was 0.27 ± 1.3 in the placebo group compared with -0.16 ± 1.3 in the Simponi group; p = 0.011).
Liječenje lijekom Simponi u dozi od 50 mg usporilo je napredovanje oštećenja perifernih zglobova u odnosu na placebo kako se pokazalo u 24. tjednu mjerenjem promjene u odnosu na početni ukupni broj vdH-S bodova na prilagođenoj ljestvici (prosječni broj bodova ± SD bio je 0,27 ± 1,3 u skupini koja je primala placebo i -0,16 ± 1,3 u skupini koja je primala Simponi; p = 0,011).
Simponi belongs to a group of medicines called ‘TNF blockers’.
Simponi pripada skupini lijekova koji se zovu "TNF blokatori".
Simponi contains the active substance golimumab.
Sadrži djelatnu tvar golimumab.
Simponi given as an initial dose of 200 mg, followed by 100 mg at week 2, then 100 mg every 4 weeks, thereafter (see section 5.1).
Daje se inicijalna doza lijeka Simponi od 200 mg, iza koje nakon 2 tjedna slijedi doza od 100 mg, a nakon toga doza od 100 mg svaka 4 tjedna (vidjeti dio 5.1).
Simponi given as an initial dose of 200 mg, followed by 100 mg at week 2, then 50 mg every 4 weeks, thereafter (see section 5.1).
Daje se inicijalna doza lijeka Simponi od 200 mg, iza koje nakon 2 tjedna slijedi doza od 100 mg, a nakon toga doza od 50 mg svaka 4 tjedna (vidjeti dio 5.1).
Simponi has not been studied in patients with CHF.
Simponi nije ispitivan u bolesnika s kongestivnim zatajenjem srca.
Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with MTX.
Simponi, u kombinaciji s metotreksatom (MTX), indiciran je za liječenje poliartikularnog juvenilnog idiopatskog artritisa u djece s tjelesnom težinom od najmanje 40 kg koja nisu na odgovarajući način odgovorila na prethodno liječenje metotreksatom.
Simponi induction only.
Samo uvodna terapija lijekom Simponi.
Simponi induction only.
Simponi 100 mg
Simponi is available as pre-filled pens and syringes (50 and 100 mg) containing a solution for injection under the skin.
Dostupan je u obliku napunjenih brizgalica i štrcaljki (50 i 100 mg) koje sadrže otopinu za supkutanu injekciju.
Simponi is given by injection under the skin (subcutaneously).
Simponi se primjenjuje injekcijom pod kožu (supkutano).
Simponi is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).
Simponi je indiciran za liječenje odraslih s teškim aktivnim aksijalnim spondiloartritisom bez radiološkog dokaza ali s objektivnim znakovima upale na koju ukazuju povišen C-reaktivni protein (CRP) i/ili nalazi oslikavanja magnetskom rezonancijom (engl. magnetic resonance imaging, MRI), koji nisu na odgovarajući način odgovorili na nesteroidne protuupalne lijekove (NSAIL-ove) ili ih ne podnose.
Simponi is indicated for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).
Simponi je indiciran za liječenje odraslih s teškim aktivnim aksijalnim spondiloartritisom bez radiološkog dokaza, ali s objektivnim znakovima upale na koju ukazuju povišen C-reaktivni protein (CRP) i/ili nalazi oslikavanja magnetskom rezonancijom (engl. magnetic resonance imaging, MRI), koji nisu na odgovarajući način odgovorili na nesteroidne protuupalne lijekove (NSAIL-ove) ili ih ne podnose.
Simponi is not recommended for children weighing less than 40 kg with polyarticular juvenile idiopathic arthritis or in children and adolescents younger than 18 years for any other condition.
Simponi se ne preporučuje u djece s poliartikularnim juvenilnim idiopatskim artritisom čija je tjelesna težina manja od 40 kg, kao ni u djece i adolescenata mlađih od 18 godina za neku drugu bolest.
Simponi is supplied as solution for injection in a single-use pre-filled pen.
Simponi dolazi na tržište u obliku otopine za injekciju u napunjenoj brizgalici za jednokratnu uporabu.
Simponi is supplied in a single use pre-filled syringe.
Simponi je dostupan u napunjenoj brizgalici za jednokratnu primjenu koja se zove SmartJect ili u napunjenoj štrcaljki za jednokratnu primjenu.
Simponi is used in adults who have not responded adequately to other treatments.
Lijek Simponi koristi se u bolesnika koji nisu primjereno odgovorili na druge terapije.
Simponi is used in adults who have not responded adequately to, or cannot use, conventional treatment; polyarticular juvenile idiopathic arthritis (a rare childhood disease causing inflammation of many joints).
Lijek Simponi koristi se u odraslih osoba koje nisu primjereno odgovorile na konvencionalnu terapiju ili je ne mogu primiti; poliartikularnog juvenilnog idiopatskog artritisa (rijetke dječje bolesti koja uzrokuje upalu velikog broja zglobova).
Simponi is used in combination with methotrexate (a medicine that acts on the immune system).
Lijek Simponi primjenjuje se u kombinaciji s metotreksatom (lijekom koji djeluje na imunosni sustav).
Simponi is used in combination with methotrexate.
Lijek Simponi primjenjuje se u kombinaciji s metotreksatom.
Simponi may have a minor influence on the ability to drive and use machines.
Simponi može malo utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
Simponi may have a minor influence on your ability to drive and use tools or machines.
Simponi može malo utjecati na sposobnost vožnje i upravljanja alatima ili strojevima.
Simponi must not be used in patients with tuberculosis, other severe infections, or moderate or severe heart failure (an inability of the heart to pump enough blood around the body).
Lijek Simponi ne smije se koristiti u bolesnika s tuberkulozom, drugim teškim infekcijama ili umjerenim ili teškim zatajenjem srca (nesposobnošću srca da pumpa dovoljne količine krvi u tijelu).
Simponi or placebo were subcutaneously administered every 4 weeks.
Simponi ili placebo primijenjeni su supkutano svaka 4 tjedna.
Simponi Patient Alert Card
Simponi kartica s upozorenjima za bolesnika
Simponi should be given concomitantly with MTX.
Samo uvodna terapija lijekom Simponi.
Simponi should be used with caution in patients with mild heart failure (NYHA class I/II).
Simponi treba davati uz oprez bolesnicima s blagim zatajenjem srca (NYHA stupanj I/II).
Simponi should be used with caution in subjects with impaired hepatic function (see section 4.2).
Simponi treba oprezno primjenjivati u bolesnika s poremećajem jetrene funkcije (vidjeti dio 4.2).
Simponi should not be given to patients with a clinically important, active infection.
Simponi se ne smije dati bolesnicima s klinički značajnom aktivnom infekcijom.
Simponi should not be used if the solution is discoloured, cloudy or containing visible foreign particles.
Simponi se ne smije primijeniti ako je otopina promijenila boju, ako je zamućena ili sadrži vidljive čestice.
Simponi treatment is to be initiated and supervised by qualified physicians experienced in the diagnosis and treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, or ulcerative colitis.
Liječenje lijekom Simponi uvodi se i provodi pod nadzorom liječnika specijaliste s iskustvom u dijagnosticiranju i liječenju reumatoidnog artritisa, poliartikularnog juvenilnog idiopatskog artritisa, psorijatičnog artritisa, ankilozantnog spondilitisa, aksijalnog spondiloartritisa bez radiološkog dokaza ili ulceroznog kolitisa.
Simponi treatment is to be initiated and supervised by qualified physicians experienced in the diagnosis and treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, or ulcerative colitis.
Liječenje lijekom Simponi uvodi se i provodi pod nadzorom liječnika specijaliste s iskustvom u dijagnosticiranju i liječenju reumatoidnog artritisa, psorijatičnog artritisa, ankilozantnog spondilitisa, aksijalnog spondiloartritisa bez radiološkog dokaza ili ulceroznog kolitisa.
Simponi treatment resulted in significant improvement in physical function as assessed by HAQ DI, as well as significant improvements in health-related quality of life as measured by the physical and mental component summary scores of the SF-36.
U ispitivanjima GO-FORWARD i GO-AFTER, klinički važni i statistički značajni odgovori na ljestvici aktivnosti bolesti (engl.
Simponi works by blocking the action of a protein called ‘tumour necrosis factor alpha’ (TNF-α).
Simponi djeluje tako što sprječava djelovanje proteina koji se zove "faktor nekroze tumora alfa" (TNF-α).
Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.
Simponi, kao jedini lijek ili u kombinaciji s metotreksatom, indiciran je za liječenje aktivnog i progresivnog psorijatičnog artritisa u odraslih bolesnika u kojih je odgovor na prethodno liječenje
Simponi, in combination with methotrexate (MTX), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.
Simponi, u kombinaciji s metotreksatom (MTX), indiciran je za: liječenje umjerenog do teškog oblika aktivnog reumatoidnog artritisa u odraslih čiji je odgovor na antireumatske lijekove koji modificiraju tijek bolesti (terapija DMARD), uključujući metotreksat, neodgovarajući. liječenje teškog, aktivnog i progresivnog reumatoidnog artritisa u odraslih koji prethodno nisu bili liječeni metotreksatom.
Simulated exposure data show that the overall AUC approximately doubles when a second dose is administered at 10, 30 and 60 minutes following the first dose.
Simulirani podaci o izloženosti pokazuju da se cjelokupni AUC približno udvostručuje kad se druga doza primijeni 10, 30 i 60 minuta nakon prve doze.
Simulated pharmacokinetic parameters for the recommended posology in children aged 3 months to less than 18 years, based on a population pharmacokinetic study are provided in tabulated format below:
Simulirani farmakokinetički parametri za doziranje preporučeno u djece od 3 mjeseca do manje od 18 godina, određeni na temelju farmakokinetičkog ispitivanja provedenog na populaciji, prikazani su u obliku tablice kako slijedi:
Simulation of 2-3 missed daily doses resulted in a median serum IgG level decrease of ≤ 4% compared to consistent daily dosing.
Simulacija 2-3 propuštene dnevne doze rezultirala je smanjenjem medijana razine IgG u serumu od ≤ 4 % u usporedbi s dosljednim dnevnim doziranjem.
Simulations by empirical Population Pharmacokinetic models suggest that comparable IgG exposure levels (AUC0-14days, Cmin 14days) may be obtained if Hizentra is administered subcutaneously every two weeks using double the weekly dose during maintenance therapy.
Simulacije prema empirijskim modelima farmakokinetičke populacije ukazuju na to da se usporedive razine izlaganja IgG (AUC0-14dana, Cmin 14dana) mogu dobiti ako se Hizentra primjenjuje supkutano svaka dva tjedna koristeći dvostruku tjednu dozu tijekom terapije održavanja.
Simulations for predicting the steady-state exposure of ivacaftor showed that by reducing the dosage from 150 mg q12h to 150 mg once daily, adults with moderate hepatic impairment would have comparable steady- state Cmin values as those obtained with a dose of 150 mg q12h in adults without hepatic impairment.
Simulacije za predviđanje izloženosti ivakaftoru u stanju dinamičke ravnoteže pokazale su da bi smanjenjem doze sa 150 mg svakih 12 sati na 150 mg jedanput na dan, odrasli s umjerenim oštećenjem funkcije jetre imali vrijednosti Cmin u stanju dinamičke ravnoteže slične onima koje se postižu dozom od 150 mg svakih 12 sati u odraslih bez oštećenja jetre.
Simulations using clinically relevant fasted conditions suggested that the mild CYP3A4 inhibitors azithromycin and fluvoxamine may increase the AUC of ibrutinib by < 2-fold.
Simulacije u klinički značajnom stanju natašte ukazale su da slabi CYP3A4 inhibitori azitromicin i fluvoksamin mogu povećati AUC ibrutiniba za < 2 puta.
Simulations using fasted conditions suggested that moderate CYP3A4 inhibitors, diltiazem, erythromycin and voriconazole, may increase the AUC of ibrutinib 5-9 fold.
Simulacije u stanju natašte pokazale su da umjereni CYP3A4 inhibitori, diltiazem, eritromicin i vorikonazol, mogu povisiti AUC ibrutiniba 5-9 puta.
Simulations using fasted conditions suggested that the strong CYP3A4 inhibitor clarithromycin may increase the AUC of ibrutinib by a factor of 14.
Simulacija u stanju natašte, pokazala je da snažni CYP3A4 inhibitor klaritromicin može povećati AUC ibrutiniba 14 puta.
Simulect 10 mg powder and solvent for solution for injection or infusion
Simulect 10 mg prašak i otapalo za otopinu za injekciju ili infuziju basiliksimab
Simulect 20 mg powder and solvent for solution for injection or infusion
Simulect 20 mg prašak i otapalo za otopinu za injekciju ili infuziju basiliksimab
Simulect can be given to children and adolescents.
Simulect se može davati djeci i adolescentima.
Simulect can be given to older patients, but the information available is limited.
Simulect se može davati starijim bolesnicima, no dostupne informacije su ograničene.
Simulect comes as a white powder in a colourless glass vial containing 10 mg of basiliximab.
Simulect je bijeli prašak u bezbojnoj staklenoj bočici koja sadržava 10 mg basiliksimaba.
Simulect comes as a white powder in a colourless glass vial containing 20 mg of basiliximab.
Simulect je bijeli prašak u bezbojnoj staklenoj bočici koja sadržava 20 mg basiliksimaba.
Simulect is given twice, in hospital, either slowly through a needle in your vein as an infusion lasting 20–30 minutes or as an intravenous injection using a syringe.
Simulect se daje dva puta, u bolnici, ili polako kroz iglu u veni kao infuzija u trajanju od 20–30 minuta ili kao intravenska injekcija pomoću štrcaljke.
Simulect works by stopping the immune cells that attack transplanted organs.
Simulect djeluje tako što zaustavlja imunološke stanice koje napadaju presađene organe.
Simultaneous administration of enoxaparin sodium and performance of spinal/epidural anaesthesia can result in intramedullary haematoma.
Istodobna primjena enoksaparinnatrija i spinalne/epiduralne anestezije može imati za posljedicu nastanak intramedularnog hematoma.
Simultaneous administration of ulipristal acetate and a P-gp substrate has not been studied and an interaction cannot be excluded.
Istovremena primjena ulipristalacetata i supstrata P-gp-a nije istražena, pa se interakcija ne može isključiti.
Simultaneous intake of nitrates or nitric oxide donors with Sildenafil ratiopharm can have severe effects on your blood pressure.
Istovremena primjena tih lijekova i lijeka Sildenafil ratiopharm mogla bi jako sniziti krvni tlak.
Simultaneous use of both vaccines increases the risk of recombination of viruses and potential emergence of new variants.
Istovremena primjena povećava rizik rekombinacije virusa i potencijalno razvijanje novih varijanta.
Simultaneous vaccination with live vaccines increases the risk of severe infections attributable to the immunosuppressive activity of Oncaspar and overall situation taking into account the underlying disease and the usually combined chemotherapy (see section 4.4).
Istodobno cijepljenje živim cjepivima povećava rizik od teških infekcija, što se može pripisati imunosupresivnoj aktivnosti Oncaspara i cjelokupnoj situaciji uzimajući u obzir temeljnu bolest i uobičajeno kombiniranu kemoterapiju (vidjeti dio 4.4).
Simultaneously press down (2a) and turn the child- resistant cap (2b) to the left to open the bottle.
Istovremeno pritisnite (2a) i zakrenite sigurnosni zatvarač za djecu (2b) na lijevo kako biste otvorili bocu.
Simultaneously press down (2a) and turn the child-resistant cap (2b) to the left to open the bottle.
Istovremeno pritisnite prema dolje (2a) i zakrenite sigurnosni zatvarač za djecu (2b) na lijevo kako biste otvorili bocu.
simultaneously with, and/or at least
uzimati u isto vrijeme s dozom
Simultaneously, liraglutide lowers inappropriately high glucagon secretion, also in a glucose­dependent manner.
Liraglutid istodobno snižava neprimjereno visoko lučenje glukagona, također u ovisnosti od glukoze.
Simultaneously, plasma concentrations of itraconazole may be increased by darunavir co-administered with low dose ritonavir.
Istodobno, koncentracije itrakonazola u plazmi mogu biti povišene uz darunavir istodobno primijenjen s niskom dozom ritonavira.
Simultaneously, plasma concentrations of itraconazole or ketoconazole may be decreased by INTELENCE.
Istovremeno, INTELENCE može smanjiti koncentracije itrakonazola ili ketokonazola u plazmi.
Simva 40
feno 145 + simva 40
Simvastatin
imvastatin
Simvastatin
Kombinacija lijeka
simvastatin 40 mg
imvastatin 40 mg
simvastatin acid Cmin not studied
Nije ispitano.
Simvastatin and lovastatin are highly dependent on CYP3A4 for their metabolism and co- administration with EVOTAZ may result in increased concentrations.
Metabolizam simvastatina i lovastatina jako ovisi o CYP3A4 pa istodobna primjena s lijekom EVOTAZ može povisiti njihove koncentracije.
Simvastatin Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone.
Simvastatin Istodobna primjena višestrukih doza od 10 mg amlodipina s 80 mg simvastatina rezultirala je povećanjem izloženosti simvastatinu za 77% u usporedbi sa samim simvastatinom.
Simvastatin is a substrate of CYP 3A4.
Simvastatin je supstrat CYP 3A4.
Simvastatin is taken up actively into the hepatocytes by the transporter OATP1B1.
Simvastatin se aktivno unosi u hepatocite transporteromOATP1B1.
simvastatin should not exceed a daily dose
doza fluvastatina, lovastatina ili simvastatina
Simvastatin to treat elevated levels of cholesterol.
Simvastatin za liječenje povišenih vrijednosti kolesterola.
Simvastatin – Co-administration of ticagrelor with simvastatin increased simvastatin Cmax by 81% and AUC by 56% and increased simvastatin acid Cmax by 64% and AUC by 52% with some individual increases equal to 2 to 3-fold.
Simvastatin – istodobna primjena tikagrelora sa simvastatinom je povećala Cmax simvastatina za 81% i AUC simvastatina za 56%, i povećala je Cmax simvastatinske kiseline za 64% i AUC simvastatinske kiseline za 52% s nekim pojedinačnim povećanjima od 2 do 3 puta.
Simvastatin ↑↑
Fluvastatin
simvastatin, lovastatin or atorvastatin (used to lower cholesterol).
simvastatin, lovastatin ili atorvastatin (koriste se za liječenje kolesterola).
Simvastatin/Efavirenz (40 mg once daily/600 mg once daily)
(40 mg jedanput na dan/600 mg
Simvastatin/Efavirenz (40 mg once daily/600 mg once daily)
dan/600 mg jedanput na dan)
Simvastatin/Efavirenz (40 mg once daily/600 mg once daily)
imvastatin/efavirenz (40 mg jedanput na dan/600 mg jedanput na dan)
Simvastatin/efavirenz (40 mg once daily/600 mg once daily)
Simvastatin/efavirenz
Simvastatin/Efavirenz (40 mg q.d./600 mg q.d.)
imvastatin/efavirenz (40 mg q.d./600 mg q.d.)
Simvastatin/Tenofovir disoproxil fumarate
simvastatin/tenofovirdizoproksil fumarat
Simvastatin:
norelgestromin (aktivni metabolit):
Simvastatin: co-administration of bosentan 125 mg twice daily for 5 days decreased the plasma concentrations of simvastatin (a CYP3A4 substrate) and its active -hydroxy acid metabolite by 34% and 46%, respectively.
Simvastatin: istodobna primjena bosentana 125 mg dvaput dnevno tijekom 5 dana dovela je do smanjenja koncentracija simvastatina u plazmi (susptrat CYP3A4) te njegovog aktivnog β- hidroksikiselinskog metabolita za 34%, odnosno 46%.
Simvastatin: co-administration of bosentan 125 mg twice daily for 5 days decreased the plasma concentrations of simvastatin (a CYP3A4 substrate) and its active -hydroxy acid metabolite by 34% and 46%, respectively.
Simvastatin: istodobna primjena bosentana 125 mg dvaput dnevno tijekom 5 dana dovela je do smanjenja koncentracija simvastatina u plazmi (susptrat CYP3A4) te njegovog aktivnog β-hidroksikiselinskog metabolita za 34%, odnosno 46%.
Simvastatin:  expected
Simvastatin: očekuje se 
Since 2007 resistance associated H275Y mutation in seasonal H1N1 strains has become widespread.
Od 2007. godine proširila se rezistencija povezana s mutacijom H275Y u soju sezonske gripe H1N1.
Since 6–mercaptopurine pharmacokinetics has not been formally studied in hepatic impairment, no specific dose recommendations can be given.
Budući da farmakokinetika merkaptopurina nije službeno ispitivana u osoba s oštećenjem funkcije jetre, ne mogu se dati posebne preporuke o doziranju.
Since 6–mercaptopurine pharmacokinetics has not been formally studied in renal impairment, no specific dose recommendations can be given.
Budući da farmakokinetika merkaptopurina nije službeno ispitivana u osoba s oštećenjem funkcije bubrega, ne mogu se dati posebne preporuke o doziranju.
Since a benign enlargement of the prostate and prostate cancer may present the same symptoms, your doctor will check you for prostate cancer before starting treatment with Silodyx.
Kako dobroćudno povećanje prostate i rak prostate mogu imati iste simptome, liječnik će Vas pregledati na rak prostate prije nego što počnete uzimati Silodyx.